{
    "abstract": "Background: Neisseria meningitidis serogroups A, B, C, W and Y cause most meningococcal disease worldwide. An investigational MenABCWY vaccine combining serogroup B antigens and a meningococcal ACWY CRM197-glycoconjugate vaccine (MenACWY-CRM) could provide protection against all 5 serogroups. Complement mediated bactericidal activity induced by MenABCWY was tested against a panel of 110 randomly-selected serogroup B strains causing invasive disease in the US to evaluate the vaccine's breadth of coverage (BoC). Methods: We conducted this observer-blind study (NCT02140762) and its extension (NCT02285777) in 8 centers in the US. Adolescents aged 10\u201318 years were randomized (1:1) to receive either 3 MenABCWY doses (MenABCWY group), on a 0, 2, 6-month (M) schedule or a single MenACWY-CRM dose at M2 and placebo at 0,6-M (Control group). MenABCWY BoC was calculated as (1 \u2212 relative risk) \u00d7 100 (relative risk = ratio between the percentage of samples seronegative at 1:4 dilution against the selected strains in the MenABCWY vs Control group). BoC was determined at 1 M and 4 M after 2 and 3 doses, using an endogenous complement serum bactericidal assay. Immunogenicity and safety were assessed. Results: 301 and 189 adolescents were vaccinated in the parent and extension study, respectively. At 1 M post-vaccination, the BoC of MenABCWY across the 110 serogroup B strains was 67% (95%CI: 65\u201369) after 2 doses and 71% (95%CI: 69\u201373) after 3 doses. BoC decreased to 44% (95%CI: 41\u201347) and 51% (95%CI: 48\u201355) at 4 M after 2 and 3 MenABCWY doses, respectively. Robust immune responses to antigen-specific test strains for each serogroup were observed at all timepoints in the MenABCWY group. No reactogenicity or safety concerns arose during the study. Conclusion: Two or 3 doses of MenABCWY showed similar BoC against the panel of invasive US serogroup B isolates and comparable immunogenicity against the antigen-specific test strains, with no safety concerns identified.",
    "author_highlights": [
        {
            "endOffset": 16619,
            "sentence": "A combined MenABCWY vaccine provides broad protection against meningococcal disease.",
            "startOffset": 16535
        },
        {
            "endOffset": 16715,
            "sentence": "Vaccine breadth of coverage (BoC) was tested against 110 randomly selected serogroup B strains.",
            "startOffset": 16620
        },
        {
            "endOffset": 16795,
            "sentence": "BoC against the panel was 67% and 71%, 1 month post-dose 2 and 3, respectively.",
            "startOffset": 16716
        },
        {
            "endOffset": 16881,
            "sentence": "BoC and persistence of the immune response was similar following either 2 or 3 doses.",
            "startOffset": 16796
        },
        {
            "endOffset": 16958,
            "sentence": "The MenABCWY vaccine was immunogenic and no safety concerns were identified.",
            "startOffset": 16882
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Gabutti"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Stefanati"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Kuhdari"
                }
            ],
            "firstpage": "E116",
            "issn": "11212233",
            "lastpage": "E120",
            "pub_year": 2015,
            "title": "Epidemiology of Neisseria meningitidis infections: Case distribution by age and relevance of carriage",
            "volume": "56"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Rabab Z.",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar A.",
                    "initial": "Z.A.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1186/1478-7954-11-17",
            "issn": "14787954",
            "pub_year": 2013,
            "title": "Global epidemiology of invasive meningococcal disease",
            "volume": "11"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.04.012",
            "firstpage": "S3",
            "issn": "1054139X",
            "lastpage": "S11",
            "pmid": "27449148",
            "pub_year": 2016,
            "title": "The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines",
            "volume": "59"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Crum-Cianflone"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Sullivan"
                }
            ],
            "doi": "10.1007/s40121-016-0107-0",
            "firstpage": "89",
            "issn": "21938229",
            "lastpage": "112",
            "pub_year": 2016,
            "title": "Meningococcal Vaccinations",
            "volume": "5"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Davide",
                    "initial": "D.",
                    "last": "Serruto"
                },
                {
                    "first": "Matthew J.",
                    "initial": "M.J.",
                    "last": "Bottomley"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Ram"
                },
                {
                    "first": "Marzia M.",
                    "initial": "M.M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.01.033",
            "firstpage": "B87",
            "issn": "0264410X",
            "lastpage": "B97",
            "pmid": "22607904",
            "pub_year": 2012,
            "title": "The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens",
            "volume": "30"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Robert G.K.",
                    "initial": "R.G.K.",
                    "last": "Donald"
                },
                {
                    "first": "Julio Cesar",
                    "initial": "J.C.",
                    "last": "Hawkins"
                },
                {
                    "first": "Li",
                    "initial": "L.",
                    "last": "Hao"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Liberator"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Jones"
                },
                {
                    "first": "Shannon L.",
                    "initial": "S.L.",
                    "last": "Harris"
                },
                {
                    "first": "John L.",
                    "initial": "J.L.",
                    "last": "Perez"
                },
                {
                    "first": "Joseph J.",
                    "initial": "J.J.",
                    "last": "Eiden"
                },
                {
                    "first": "Kathrin U.",
                    "initial": "K.U.",
                    "last": "Jansen"
                },
                {
                    "first": "Annaliesa S.",
                    "initial": "A.S.",
                    "last": "Anderson"
                }
            ],
            "doi": "10.1080/21645515.2017.1264750",
            "firstpage": "255",
            "issn": "21645515",
            "lastpage": "265",
            "pmid": "27960595",
            "pub_year": 2017,
            "title": "Meningococcal serogroup B vaccines: Estimating breadth of coverage",
            "volume": "13"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Matt",
                    "initial": "M.",
                    "last": "Shirley"
                },
                {
                    "first": "Sohita",
                    "initial": "S.",
                    "last": "Dhillon"
                }
            ],
            "doi": "10.1007/s40259-015-0139-0",
            "firstpage": "353",
            "issn": "11738804",
            "lastpage": "361",
            "pmid": "26394633",
            "pub_year": 2015,
            "title": "Bivalent rLP2086 Vaccine (Trumenba\u00ae): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years",
            "volume": "29"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Philip S.",
                    "initial": "P.S.",
                    "last": "Watson"
                },
                {
                    "first": "David P.J.",
                    "initial": "D.P.J.",
                    "last": "Turner"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.11.057",
            "firstpage": "875",
            "issn": "0264410X",
            "lastpage": "880",
            "pmid": "26686570",
            "pub_year": 2016,
            "title": "Clinical experience with the meningococcal B vaccine, Bexsero\u00ae: Prospects for reducing the burden of meningococcal serogroup B disease",
            "volume": "34"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "O'Ryan"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Stoddard"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1007/s40265-013-0155-7",
            "firstpage": "15",
            "issn": "00126667",
            "lastpage": "30",
            "pmid": "24338083",
            "pub_year": 2014,
            "title": "A multi-component meningococcal serogroup B vaccine (4CMenB): The clinical development program",
            "volume": "74"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Vega",
                    "initial": "V.",
                    "last": "Masignani"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                }
            ],
            "doi": "10.1080/14760584.2017.1308828",
            "firstpage": "433",
            "issn": "14760584",
            "lastpage": "451",
            "pmid": "28375029",
            "pub_year": 2017,
            "title": "Emerging experience with meningococcal serogroup B protein vaccines",
            "volume": "16"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Amanda C.",
                    "initial": "A.C.",
                    "last": "Cohn"
                },
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Ismael R.",
                    "initial": "I.R.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Elizabeth Z.",
                    "initial": "E.Z.",
                    "last": "Briere"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Cody Meissner"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                }
            ],
            "issn": "10575987",
            "pmid": "23515099",
            "pub_year": 2013,
            "title": "Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)",
            "volume": "62"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Lorry",
                    "initial": "L.",
                    "last": "Rubin"
                },
                {
                    "first": "Temitope",
                    "initial": "T.",
                    "last": "Folaranmi"
                },
                {
                    "first": "Ismael R.",
                    "initial": "I.R.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Manisha",
                    "initial": "M.",
                    "last": "Patel"
                },
                {
                    "first": "Stacey W.",
                    "initial": "S.W.",
                    "last": "Martin"
                }
            ],
            "doi": "10.15585/mmwr.mm6441a3",
            "firstpage": "1171",
            "issn": "01492195",
            "lastpage": "1176",
            "pmid": "26492381",
            "pub_year": 2015,
            "title": "Use of serogroup B meningococcal vaccines in adolescents and young adults: Recommendations of the advisory committee on immunization practices, 2015",
            "volume": "64"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Monica E.",
                    "initial": "M.E.",
                    "last": "Patton"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Stephens"
                },
                {
                    "first": "Kelly",
                    "initial": "K.",
                    "last": "Moore"
                },
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                }
            ],
            "doi": "10.15585/mmwr.mm6619a6",
            "firstpage": "509",
            "issn": "01492195",
            "lastpage": "513",
            "pmid": "28520709",
            "pub_year": 2017,
            "title": "Updated recommendations for use of MenB-FHBP serogroup B meningococcal vaccine \u2014 Advisory committee on immunization practices, 2016",
            "volume": "66"
        },
        "b0070": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1307",
            "firstpage": "1307",
            "issn": "00221007",
            "lastpage": "1326",
            "pmid": "4977280",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. I. The role of humoral antibodies.",
            "volume": "129"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Sydel R.",
                    "initial": "S.R.",
                    "last": "Parikh"
                },
                {
                    "first": "Lynne",
                    "initial": "L.",
                    "last": "Newbold"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Slater"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Stella"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Moschioni"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Rosita",
                    "initial": "R.",
                    "last": "De Paola"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Serino"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Gray"
                },
                {
                    "first": "Stephen A.",
                    "initial": "S.A.",
                    "last": "Clark"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/S1473-3099(17)30170-6",
            "firstpage": "754",
            "issn": "14733099",
            "lastpage": "762",
            "pmid": "28366725",
            "pub_year": 2017,
            "title": "Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment",
            "volume": "17"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Sydel R.",
                    "initial": "S.R.",
                    "last": "Parikh"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Andrews"
                },
                {
                    "first": "Kazim",
                    "initial": "K.",
                    "last": "Beebeejaun"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Charlotte",
                    "initial": "C.",
                    "last": "Ward"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "White"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                }
            ],
            "doi": "10.1016/S0140-6736(16)31921-3",
            "firstpage": "2775",
            "issn": "01406736",
            "lastpage": "2782",
            "pmid": "28100432",
            "pub_year": 2016,
            "title": "Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study",
            "volume": "388"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Duccio",
                    "initial": "D.",
                    "last": "Medini"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Stella"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Wassil"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.04.015",
            "firstpage": "2629",
            "issn": "0264410X",
            "lastpage": "2636",
            "pmid": "25882169",
            "pub_year": 2015,
            "title": "MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine",
            "volume": "33"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Giacomo",
                    "initial": "G.",
                    "last": "Frosi"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Biolchi"
                },
                {
                    "first": "Morena Lo",
                    "initial": "M.L.",
                    "last": "Sapio"
                },
                {
                    "first": "Fabio",
                    "initial": "F.",
                    "last": "Rigat"
                },
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Gilchrist"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Marzia Monica",
                    "initial": "M.M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Duccio",
                    "initial": "D.",
                    "last": "Medini"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.08.006",
            "firstpage": "4968",
            "issn": "0264410X",
            "lastpage": "4974",
            "pmid": "23954380",
            "pub_year": 2013,
            "title": "Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage",
            "volume": "31"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Izabela",
                    "initial": "I.",
                    "last": "Wa\u015bko"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Hong"
                },
                {
                    "first": "Rosita",
                    "initial": "R.",
                    "last": "De Paola"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Stella"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Moschioni"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Skoczy\u0144ska"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.11.070",
            "firstpage": "510",
            "issn": "0264410X",
            "lastpage": "515",
            "pmid": "26686998",
            "pub_year": 2016,
            "title": "High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland",
            "volume": "34"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Julie A.",
                    "initial": "J.A.",
                    "last": "Bettinger"
                },
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Scheifele"
                },
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Wendy",
                    "initial": "W.",
                    "last": "Vaudry"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Duccio",
                    "initial": "D.",
                    "last": "Medini"
                },
                {
                    "first": "Raymond",
                    "initial": "R.",
                    "last": "Tsang"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.03.063",
            "firstpage": "124",
            "issn": "0264410X",
            "lastpage": "130",
            "pmid": "23588089",
            "pub_year": 2013,
            "title": "Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)",
            "volume": "32"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Gray"
                },
                {
                    "first": "Edward B.",
                    "initial": "E.B.",
                    "last": "Kaczmarski"
                },
                {
                    "first": "Malcolm",
                    "initial": "M.",
                    "last": "Guiver"
                },
                {
                    "first": "Pamela J.",
                    "initial": "P.J.",
                    "last": "Vallely"
                },
                {
                    "first": "Philipp",
                    "initial": "P.",
                    "last": "Oster"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Stefania",
                    "initial": "S.",
                    "last": "Bambini"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Muzzi"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1128/CVI.00027-10",
            "firstpage": "919",
            "issn": "15566811",
            "lastpage": "929",
            "pmid": "20375242",
            "pub_year": 2010,
            "title": "Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine",
            "volume": "17"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Stan L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Shane",
                    "initial": "S.",
                    "last": "Christensen"
                },
                {
                    "first": "Bikash",
                    "initial": "B.",
                    "last": "Verma"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Pavitra",
                    "initial": "P.",
                    "last": "Keshavan"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.02.049",
            "firstpage": "2175",
            "issn": "0264410X",
            "lastpage": "2182",
            "pmid": "25744224",
            "pub_year": 2015,
            "title": "Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination",
            "volume": "33"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Gowrisankar",
                    "initial": "G.",
                    "last": "Rajam"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Stella"
                },
                {
                    "first": "Ellie",
                    "initial": "E.",
                    "last": "Kim"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Paulos"
                },
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Boccadifuoco"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Serino"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Carlone"
                },
                {
                    "first": "Duccio",
                    "initial": "D.",
                    "last": "Medini"
                }
            ],
            "doi": "10.1128/mSphere.00261-17",
            "issn": "23795042",
            "pub_year": 2017,
            "title": "Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States",
            "volume": "2"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Wang"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Cohn"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Lubomira",
                    "initial": "L.",
                    "last": "Andrew"
                },
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Zhao"
                },
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Schmink"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Muzzi"
                },
                {
                    "first": "Stefania",
                    "initial": "S.",
                    "last": "Bambini"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Murphy"
                },
                {
                    "first": "Susan K.",
                    "initial": "S.K.",
                    "last": "Hoiseth"
                },
                {
                    "first": "Kathrin U.",
                    "initial": "K.U.",
                    "last": "Jansen"
                },
                {
                    "first": "Annaliesa S.",
                    "initial": "A.S.",
                    "last": "Anderson"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Leonard W.",
                    "initial": "L.W.",
                    "last": "Mayer"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.04.092",
            "firstpage": "4739",
            "issn": "0264410X",
            "lastpage": "4744",
            "pub_year": 2011,
            "title": "Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States",
            "volume": "29"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Puiying A.",
                    "initial": "P.A.",
                    "last": "Mak"
                },
                {
                    "first": "George F.",
                    "initial": "G.F.",
                    "last": "Santos"
                },
                {
                    "first": "Kelly Anne",
                    "initial": "K.A.",
                    "last": "Masterman"
                },
                {
                    "first": "Jeff",
                    "initial": "J.",
                    "last": "Janes"
                },
                {
                    "first": "Bill",
                    "initial": "B.",
                    "last": "Wacknov"
                },
                {
                    "first": "Kay",
                    "initial": "K.",
                    "last": "Vienken"
                },
                {
                    "first": "Marzia",
                    "initial": "M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Ann E.",
                    "initial": "A.E.",
                    "last": "Herman"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Cooke"
                },
                {
                    "first": "M. Lamine",
                    "initial": "M.L.",
                    "last": "Mbow"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Donnelly"
                }
            ],
            "doi": "10.1128/CVI.05028-11",
            "firstpage": "1252",
            "issn": "15566811",
            "lastpage": "1260",
            "pmid": "21715580",
            "pub_year": 2011,
            "title": "Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis",
            "volume": "18"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Stan L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Leszek",
                    "initial": "L.",
                    "last": "Szenborn"
                },
                {
                    "first": "Wendy",
                    "initial": "W.",
                    "last": "Daly"
                },
                {
                    "first": "Teresa",
                    "initial": "T.",
                    "last": "Jackowska"
                },
                {
                    "first": "Diego",
                    "initial": "D.",
                    "last": "D'Agostino"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.03.001",
            "firstpage": "2500",
            "issn": "0264410X",
            "lastpage": "2510",
            "pmid": "25795256",
            "pub_year": 2015,
            "title": "A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial",
            "volume": "33"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Saez-Llorens"
                },
                {
                    "first": "Diana Catalina Aguilera",
                    "initial": "D.C.A.",
                    "last": "Vaca"
                },
                {
                    "first": "Katia",
                    "initial": "K.",
                    "last": "Abarca"
                },
                {
                    "first": "Emmanuelle",
                    "initial": "E.",
                    "last": "Maho"
                },
                {
                    "first": "Maria Gabriela",
                    "initial": "M.G.",
                    "last": "Gra\u00f1a"
                },
                {
                    "first": "Esther",
                    "initial": "E.",
                    "last": "Heijnen"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1080/21645515.2015.1029686",
            "firstpage": "1507",
            "issn": "21645515",
            "lastpage": "1517",
            "pmid": "25969894",
            "pub_year": 2015,
            "title": "Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents",
            "volume": "11"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Saez-Llorens"
                },
                {
                    "first": "Diana Catalina",
                    "initial": "D.C.",
                    "last": "Aguilera Vaca"
                },
                {
                    "first": "Katia",
                    "initial": "K.",
                    "last": "Abarca"
                },
                {
                    "first": "Emmanuelle",
                    "initial": "E.",
                    "last": "Maho"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1097/INF.0000000000000822",
            "firstpage": "e264",
            "issn": "08913668",
            "lastpage": "e278",
            "pmid": "26135245",
            "pub_year": 2015,
            "title": "Persistence of meningococcal antibodies and response to a third dose after a two-dose vaccination series with investigational MenABCWY vaccine formulations in adolescents",
            "volume": "34"
        },
        "b0145": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1327",
            "firstpage": "1327",
            "issn": "00221007",
            "lastpage": "1348",
            "pmid": "4977281",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. II. Development of natural immunity.",
            "volume": "129"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Hope H.",
                    "initial": "H.H.",
                    "last": "Biswas"
                },
                {
                    "first": "George S.",
                    "initial": "G.S.",
                    "last": "Han"
                },
                {
                    "first": "Kristen",
                    "initial": "K.",
                    "last": "Wendorf"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Winter"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Zipprich"
                },
                {
                    "first": "Tara",
                    "initial": "T.",
                    "last": "Perti"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Martinez"
                },
                {
                    "first": "Aileen",
                    "initial": "A.",
                    "last": "Arellano"
                },
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "Kyle"
                },
                {
                    "first": "Peng",
                    "initial": "P.",
                    "last": "Zhang"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Harriman"
                }
            ],
            "doi": "10.15585/mmwr.mm6520a3",
            "firstpage": "520",
            "issn": "01492195",
            "lastpage": "521",
            "pmid": "27227576",
            "pub_year": 2016,
            "title": "Outbreak of serogroup B meningococcal disease at a university\u2014 California, 2016",
            "volume": "65"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Lucy A.",
                    "initial": "L.A.",
                    "last": "McNamara"
                },
                {
                    "first": "Alice M.",
                    "initial": "A.M.",
                    "last": "Shumate"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Johnsen"
                },
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Manisha",
                    "initial": "M.",
                    "last": "Patel"
                },
                {
                    "first": "Tina",
                    "initial": "T.",
                    "last": "Bhavsar"
                },
                {
                    "first": "Amanda C.",
                    "initial": "A.C.",
                    "last": "Cohn"
                },
                {
                    "first": "Jill",
                    "initial": "J.",
                    "last": "Dinitz-Sklar"
                },
                {
                    "first": "Jonathan",
                    "initial": "J.",
                    "last": "Duffy"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Finnie"
                },
                {
                    "first": "Denise",
                    "initial": "D.",
                    "last": "Garon"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hary"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Hu"
                },
                {
                    "first": "Hajime",
                    "initial": "H.",
                    "last": "Kamiya"
                },
                {
                    "first": "Hye Joo",
                    "initial": "H.J.",
                    "last": "Kim"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Kolligian"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Neglia"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Oakley"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Wagner"
                },
                {
                    "first": "Kathy",
                    "initial": "K.",
                    "last": "Wagner"
                },
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Wang"
                },
                {
                    "first": "Yon",
                    "initial": "Y.",
                    "last": "Yu"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Montana"
                },
                {
                    "first": "Christina",
                    "initial": "C.",
                    "last": "Tan"
                },
                {
                    "first": "Robin",
                    "initial": "R.",
                    "last": "Izzo"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                }
            ],
            "doi": "10.1542/peds.2014-4015",
            "firstpage": "798",
            "issn": "00314005",
            "lastpage": "804",
            "pmid": "25917990",
            "pub_year": 2015,
            "title": "First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak",
            "volume": "135"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Heidi M.",
                    "initial": "H.M.",
                    "last": "Soeters"
                },
                {
                    "first": "Lucy A.",
                    "initial": "L.A.",
                    "last": "McNamara"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Whaley"
                },
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Wang"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Alexander-Scott"
                },
                {
                    "first": "Koren V.",
                    "initial": "K.V.",
                    "last": "Kanadanian"
                },
                {
                    "first": "Catherine M.",
                    "initial": "C.M.",
                    "last": "Kelleher"
                },
                {
                    "first": "Jessica",
                    "initial": "J.",
                    "last": "Macneil"
                },
                {
                    "first": "Stacey W.",
                    "initial": "S.W.",
                    "last": "Martin"
                },
                {
                    "first": "Nathan",
                    "initial": "N.",
                    "last": "Raines"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Sears"
                },
                {
                    "first": "Cynthia",
                    "initial": "C.",
                    "last": "Vanner"
                },
                {
                    "first": "Jeni",
                    "initial": "J.",
                    "last": "Vuong"
                },
                {
                    "first": "Utpala",
                    "initial": "U.",
                    "last": "Bandy"
                },
                {
                    "first": "Kenneth",
                    "initial": "K.",
                    "last": "Sicard"
                },
                {
                    "first": "Manisha",
                    "initial": "M.",
                    "last": "Patel"
                }
            ],
            "firstpage": "606",
            "issn": "01492195",
            "lastpage": "607",
            "pmid": "26068563",
            "pub_year": 2015,
            "title": "Serogroup b meningococcal disease outbreak and carriage evaluation at a college \u2014 rhode island, 2015",
            "volume": "64"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1128/CDLI.10.5.780-786.2003",
            "firstpage": "780",
            "issn": "1071412X",
            "lastpage": "786",
            "pmid": "12965904",
            "pub_year": 2003,
            "title": "Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England",
            "volume": "10"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Kate L.",
                    "initial": "K.L.",
                    "last": "Seib"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Scarselli"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Vega",
                    "initial": "V.",
                    "last": "Masignani"
                }
            ],
            "doi": "10.1586/14760584.2015.1016915",
            "firstpage": "841",
            "issn": "14760584",
            "lastpage": "859",
            "pmid": "25704037",
            "pub_year": 2015,
            "title": "Neisseria meningitidis factor H-binding protein fHbp: Key virulence factor and vaccine antigen",
            "volume": "14"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Scott R.",
                    "initial": "S.R.",
                    "last": "Barnum"
                }
            ],
            "doi": "10.1016/j.pharmthera.2016.11.014",
            "firstpage": "63",
            "issn": "01637258",
            "lastpage": "72",
            "pmid": "27914981",
            "pub_year": 2017,
            "title": "Complement: A primer for the coming therapeutic revolution",
            "volume": "172"
        }
    },
    "body_text": [
        {
            "endOffset": 23379,
            "parents": [],
            "secId": "s0005",
            "sentence": "We calculated the vaccine\u2019s BoC as the reduction in the percentage of samples without SBA activity at 1:4 dilution against the selected strains in participants receiving MenABCWY versus those receiving MenACWY-CRM as control.",
            "startOffset": 23154,
            "title": "Introduction"
        },
        {
            "endOffset": 41070,
            "parents": [],
            "secId": "s0085",
            "sentence": "As expected, immune responses to serogroups A, C, W and Y were higher in the MenABCWY group than in the Control group at all post-vaccination timepoints, due to the higher number of vaccine doses administered.",
            "startOffset": 40861,
            "title": "Discussion"
        },
        {
            "endOffset": 22408,
            "parents": [],
            "secId": "s0005",
            "sentence": "Testing large panels of strains is technically difficult due to the need of suitable strain-specific, seronegative human exogenous complement source and the limited quantities of serum from children and infant clinical trials.",
            "startOffset": 22182,
            "title": "Introduction"
        },
        {
            "endOffset": 20972,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 20971,
                    "startOffset": 20967
                }
            },
            "secId": "s0005",
            "sentence": "Serum bactericidal activity (SBA) from assays using human complement (hSBA) are used to evaluate immunogenicity for the licensure of meningococcal vaccines, and an hSBA titer of 4 is considered the correlate of protection against meningococcal disease [14].",
            "startOffset": 20715,
            "title": "Introduction"
        },
        {
            "endOffset": 22959,
            "parents": [],
            "secId": "s0005",
            "sentence": "In this study we used this method as a novel approach to evaluate the breadth of coverage (BoC) provided by vaccination with 2 and 3 doses of the investigational MenABCWY vaccine in adolescents, against a broad panel of 110 US endemic N. meningitidis serogroup B strains isolated from individuals with IMD, instead of a determination using the MATS laboratory assay.",
            "startOffset": 22593,
            "title": "Introduction"
        },
        {
            "endOffset": 44561,
            "parents": [],
            "secId": "s0095",
            "sentence": "Menveo and Bexsero are trademarks of GSK group of companies.",
            "startOffset": 44501,
            "title": "Trademark statement"
        },
        {
            "endOffset": 34466,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Of these, 189 adolescents were enrolled in the extension study and received vaccination (Fig. 2).",
            "startOffset": 34369,
            "title": "Demographics"
        },
        {
            "endOffset": 34368,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Of the 305 adolescents enrolled in the parent study, 301 received \u22651 dose of study vaccine.",
            "startOffset": 34277,
            "title": "Demographics"
        },
        {
            "endOffset": 24804,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2018.07.016.",
            "startOffset": 24670,
            "title": "Study design and participants"
        },
        {
            "endOffset": 34254,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "All analyses were performed using SAS 9.2 version 3.5.",
            "startOffset": 34200,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 41672,
            "parents": [],
            "secId": "s0085",
            "sentence": "No concerning safety signals were identified; the one reported SAE occurring following administration of MenACWY-CRM was considered unrelated to study vaccination.",
            "startOffset": 41509,
            "title": "Discussion"
        },
        {
            "endOffset": 43753,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 43695,
                    "startOffset": 43691
                }
            },
            "secId": "s0085",
            "sentence": "A high coverage (95%) of serogroup B strains was also predicted for 4CMenB by MATS, in a panel of 442 US strains [23] from which the strains tested in our study were selected.",
            "startOffset": 43578,
            "title": "Discussion"
        },
        {
            "endOffset": 25531,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "An interactive response technology was used to perform randomization of the participants into one of the groups, prior to vaccination, and to generate a randomized list of strains for enc-hSBA testing for each participant.",
            "startOffset": 25309,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30918,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A genotypic and phenotypic strain characterization of the MenABCWY antigen-specific laboratory strains used for the HT-hSBA is provided in Table S2.",
            "startOffset": 30770,
            "title": "Serological assays"
        },
        {
            "endOffset": 37858,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Across all post-vaccination timepoints, 89\u2013100%of participants in the MenABCWY group had HT-hSBA titers \u22651:8 against A CWY serogroups, except for serogroup A at 4 months post-second (69%) and third dose (86%); GMTs were higher in the MenABCWY group compared to the control group (Tables S6, S7).",
            "startOffset": 37563,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 34200,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "With this sample size, the parent study had >99% power to detect a BoC of 33% across the 110 serogroup B strains, with the lower limit of the 2-sided 95% confidence interval (CI) above the pre-specified study success criteria for the primary objective (>10%).",
            "startOffset": 33941,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35073,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The BoC was 44% (95% CI: 41\u201347) at 4 months post-second MenABCWY dose, and 71% (95% CI: 69\u201373) and 51% (95% CI: 48\u201355), at 1 and 4 months post-third vaccination, respectively (Table 2).",
            "startOffset": 34888,
            "title": "Overall breadth of coverage against serogroup B strains panel"
        },
        {
            "endOffset": 20288,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 20287,
                    "startOffset": 20280
                },
                "b0060": {
                    "endOffset": 20287,
                    "startOffset": 20280
                },
                "b0065": {
                    "endOffset": 20287,
                    "startOffset": 20280
                }
            },
            "secId": "s0005",
            "sentence": "In the United States (US), routine vaccination against ACWY serogroups is recommended at 11\u201312 years of age (with a booster at 16\u201319 years), while vaccination against serogroup B may be administered to individuals aged 10\u201325 years [11\u201313].",
            "startOffset": 20049,
            "title": "Introduction"
        },
        {
            "endOffset": 34887,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The overall BoC provided by MenABCWY against the randomly\u2013selected panel of serogroup B strains at 1 month post-second dose was 67% (95% CI: 65\u201369); as the lower limit of the 95% CI was \u226510%, the primary objective was demonstrated.",
            "startOffset": 34656,
            "title": "Overall breadth of coverage against serogroup B strains panel"
        },
        {
            "endOffset": 27999,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The investigational vaccine MenABCWY was prepared aseptically just prior to administration by reconstituting the lyophilized MenACWY component with a liquid suspension containing serogroup B components (Text S2).",
            "startOffset": 27787,
            "title": "Vaccines"
        },
        {
            "endOffset": 27787,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The placebo was a 0.9% saline solution.",
            "startOffset": 27748,
            "title": "Vaccines"
        },
        {
            "endOffset": 19293,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 19292,
                    "startOffset": 19287
                },
                "b0010": {
                    "endOffset": 19292,
                    "startOffset": 19287
                }
            },
            "secId": "s0005",
            "sentence": "Rates of invasive meningococcal disease (IMD) are highest in young infants, with a secondary peak seen in adolescents [1,2].",
            "startOffset": 19169,
            "title": "Introduction"
        },
        {
            "endOffset": 39945,
            "parents": [],
            "secId": "s0085",
            "sentence": "Overall, the baseline levels of naturally acquired anti-meningococcal antibodies were quite low in this population of US adolescents, and an assessment performed at 1:4 dilution was adequate to calculate the BoC afforded by the MenABCWY vaccine.",
            "startOffset": 39700,
            "title": "Discussion"
        },
        {
            "endOffset": 34592,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The demographic and baseline characteristics were balanced between groups, in both the parent and extension studies (Table 1).",
            "startOffset": 34466,
            "title": "Demographics"
        },
        {
            "endOffset": 35874,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "At all timepoints, for the same percentage of tested strains in each of the 2 groups, the percentage of participants with positive enc-hSBA results was higher in the MenABCWY group than in the Control group (e.g., at all timepoints, 1% of participants in the Control group had samples with >80% of strains killed; Fig. 3).",
            "startOffset": 35552,
            "title": "Participants\u2019 distribution by percentages of strains killed"
        },
        {
            "endOffset": 44482,
            "parents": [],
            "secId": "s0090",
            "sentence": "Our results indicate that the MenABCWY vaccine could provide protection against the majority of US endemic serogroup B strains.",
            "startOffset": 44355,
            "title": "Conclusions"
        },
        {
            "endOffset": 37942,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Calculated geometric mean ratios at each timepoint are presented in Tables S7, S8 .",
            "startOffset": 37859,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31736,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A genotypic and phenotypic strain characterization of the MenABCWY antigen-specific laboratory strains used for the HT-hSBA is provided in Table S2.",
            "startOffset": 31588,
            "title": "Serological assays"
        },
        {
            "endOffset": 27202,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The strain-specific BoC, as well as the distribution of the participants by the percentage of serogroup B invasive disease strains killed at 1:4 dilution, were assessed using enc-hSBA prior to vaccination with MenABCWY, and at 1 and 4 months after the second and third dose, as compared to a single MenACWY-CRM dose.",
            "startOffset": 26886,
            "title": "Study objectives"
        },
        {
            "endOffset": 33839,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Assuming a 20% drop-out rate, this ensured approximately 120 evaluable participants per group for the parent study.",
            "startOffset": 33724,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 38344,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "One serious AE (mild pharyngitis, occurring 24 days after the MenACWY-CRM dose and resolved after 16 days from onset) was reported and assessed as non-related to vaccination (Table S9).",
            "startOffset": 38159,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 26305,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Protocol summaries are available at http://www.gsk-clinicalstudyregister.com (study IDs 205231, 205232).3",
            "startOffset": 25837,
            "title": "Study design and participants"
        },
        {
            "endOffset": 25836,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Informed consent/assent forms and protocols were reviewed by independent review boards at each site.",
            "startOffset": 25736,
            "title": "Study design and participants"
        },
        {
            "endOffset": 38419,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The most frequent local and general AEs were pain and headache and fatigue.",
            "startOffset": 38344,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 41399,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 41398,
                    "startOffset": 41391
                },
                "b0135": {
                    "endOffset": 41398,
                    "startOffset": 41391
                }
            },
            "secId": "s0085",
            "sentence": "These results are consistent with prior reported incidence of pain in 50\u201392% of vaccinated individuals following 2 MenABCWY doses [26,27].",
            "startOffset": 41261,
            "title": "Discussion"
        },
        {
            "endOffset": 23870,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "It consisted of a parent study in which adolescents were randomized (1:1) to receive 2 doses of MenABCWY (MenABCWY group) or 1 dose of placebo and 1 dose of MenACWY-CRM (Control group), administered 2 months apart.",
            "startOffset": 23656,
            "title": "Study design and participants"
        },
        {
            "endOffset": 42734,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 42653,
                    "startOffset": 42649
                },
                "b0175": {
                    "endOffset": 42733,
                    "startOffset": 42729
                }
            },
            "secId": "s0085",
            "sentence": "Although we directly measured bactericidal activity against epidemiologically-relevant serogroup B strains, the total number of randomly selected individuals tested for each strain was limited (19\u201356 different samples/strain) and may not be representative for the overall population, considering the polymorphism of human factor H [34] and complement encoding genes and the variability of complement components [35].",
            "startOffset": 42318,
            "title": "Discussion"
        },
        {
            "endOffset": 21783,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 21711,
                    "startOffset": 21707
                },
                "b0090": {
                    "endOffset": 21782,
                    "startOffset": 21778
                }
            },
            "secId": "s0005",
            "sentence": "In addition, the Meningococcal Antigen Typing System (MATS) assay, an in vitro laboratory assay which measures the level of antigen expression and antigenic diversity of vaccine antigens estimated a strain coverage of 66\u201391% for 4CMenB in 13 countries, including the US [17], although predicted strain coverage is known to be underestimated [18].",
            "startOffset": 21437,
            "title": "Introduction"
        },
        {
            "endOffset": 25309,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A complete list of inclusion/exclusion criteria is presented in the Supplementary Material, Text S1.",
            "startOffset": 25209,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36610,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "For the majority of tested serogroup B strains, comparable strain-specific BoCs were observed at 1 month after 2 and 3 doses and at 4 months after 2 and 3 doses, respectively (e. g., 59.1% and 65.5%, and 38.2% and 46.4% had a strain-specific BoC >60% at study months 3 and 7 and 6 and 10, respectively; Table S3).",
            "startOffset": 36297,
            "title": "Strain-specific breadth of coverage"
        },
        {
            "endOffset": 37284,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Calculated geometric mean ratios at each timepoint are presented in Tables S7, S8.",
            "startOffset": 37202,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30433,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 30139,
                    "startOffset": 30135
                }
            },
            "secId": "s0035",
            "sentence": "The high throughput hSBA (HT-hSBA) [25] using human plasma as the source of exogenous complement (plasmapheresis was performed using citrate as the anticoagulant and heparin was included in the buffer of the HT-hSBA) was used to measure antibodies against test strains specific for serogroup B vaccine components and ACWY serogroups.",
            "startOffset": 30100,
            "title": "Serological assays"
        },
        {
            "endOffset": 25735,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Both the parent study and its extension were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki and are registered at www.clinicaltrials.gov (NCT02140762 and NCT02285777).",
            "startOffset": 25531,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29025,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 28922,
                    "startOffset": 28918
                },
                "b0120": {
                    "endOffset": 29024,
                    "startOffset": 29020
                }
            },
            "secId": "s0030",
            "sentence": "In total, 442 serogroup B strains [23] were obtained from a systematically collected CDC repository of US IMD strains from 2000 to 2008 [24].",
            "startOffset": 28884,
            "title": "110 strain panel"
        },
        {
            "endOffset": 24569,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from participants aged \u226518 years or parents/legal guardians of 10\u201317-year-olds prior to enrollment, and assent was obtained from participants \u226418 years of age.",
            "startOffset": 24372,
            "title": "Study design and participants"
        },
        {
            "endOffset": 42317,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 42316,
                    "startOffset": 42309
                },
                "b0165": {
                    "endOffset": 42316,
                    "startOffset": 42309
                }
            },
            "secId": "s0085",
            "sentence": "Also, the threshold of SBA 1:4 dilution used in our study to define response to each strain likely underestimates protection, as a lower SBA was not shown to indicate susceptibility to meningococcal disease [14,33].",
            "startOffset": 42102,
            "title": "Discussion"
        },
        {
            "endOffset": 43577,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 43576,
                    "startOffset": 43569
                },
                "b0080": {
                    "endOffset": 43576,
                    "startOffset": 43569
                }
            },
            "secId": "s0085",
            "sentence": "We therefore expect the BoC provided by 2 4CMenB doses to be higher than that of 2 doses of the MenABCWY combination vaccine against the 110 US strain panel, also taking into consideration the effectiveness data emerging following the implementation of 4CMenB vaccination in the pediatric immunization schedule in the United Kingdom [15,16].",
            "startOffset": 43236,
            "title": "Discussion"
        },
        {
            "endOffset": 31910,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Solicited local and systemic AEs were collected within 7 days and unsolicited AEs within 30 days post-vaccination.",
            "startOffset": 31796,
            "title": "Safety"
        },
        {
            "endOffset": 24371,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Eligible participants in the parent study were healthy adolescents aged 10\u201318 years; participants who had received the vaccines according to protocol and completed the study were eligible for the extension.",
            "startOffset": 24165,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32878,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "A detailed description of the method used to calculate the overall and strain-specific BoCs is provided in Text S5.",
            "startOffset": 32763,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20715,
            "parents": [],
            "secId": "s0005",
            "sentence": "A combination vaccine containing a meningococcal ACWY CRM197-glycoconjugate vaccine (MenACWY-CRM) and the 4CMenB vaccine (MenABCWY) has been developed to provide protection against the 5 most epidemiologically-relevant serogroups, with a reduced number of doses compared with current US recommendations, which will simplify the vaccination schedule and potentially improve compliance with vaccination and vaccination coverage.",
            "startOffset": 20289,
            "title": "Introduction"
        },
        {
            "endOffset": 33321,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The overall BoC was defined as (1 \u2212 relative risk) \u00d7 100, where the relative risk was calculated as the average (across the 110 strains in the panel) of the ratio between the percentages of samples without SBA at 1:4 dilution in the MenABCWY group and the percentages of samples without SBA at 1:4 dilution in the Control group, using a generalized linear model with treatment group and strain as independent variables, and adjusted by centre.",
            "startOffset": 32878,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 19785,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 19622,
                    "startOffset": 19619
                },
                "b0025": {
                    "endOffset": 19784,
                    "startOffset": 19781
                }
            },
            "secId": "s0005",
            "sentence": "Several quadrivalent vaccines for serogroups ACWY have been licensed in many countries [4], while the development of serogroup B vaccines was more challenging due to similarities of the capsular polysaccharide with components of human glycoproteins [5].",
            "startOffset": 19532,
            "title": "Introduction"
        },
        {
            "endOffset": 20048,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 19963,
                    "startOffset": 19957
                },
                "b0050": {
                    "endOffset": 19963,
                    "startOffset": 19957
                }
            },
            "secId": "s0005",
            "sentence": "The multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero, GSK) [9,10] was introduced into the national infant immunization schedule in the United Kingdom.",
            "startOffset": 19881,
            "title": "Introduction"
        },
        {
            "endOffset": 40662,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 40661,
                    "startOffset": 40657
                }
            },
            "secId": "s0085",
            "sentence": "A third dose of MenABCWY administered at 4 months after the second dose elicited a robust immune response to all vaccine antigens; however, at 1 year post-first vaccination, the persistence of antibody levels was similar among adolescents receiving 2 or 3 doses [28].",
            "startOffset": 40395,
            "title": "Discussion"
        },
        {
            "endOffset": 43969,
            "parents": [],
            "secId": "s0085",
            "sentence": "However, the comparison is also limited by differences and particularities of each method and further testing using the same panels of strains are needed to establish a correlation between enc-hSBA and MATS results.",
            "startOffset": 43754,
            "title": "Discussion"
        },
        {
            "endOffset": 19880,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 19879,
                    "startOffset": 19874
                },
                "b0035": {
                    "endOffset": 19879,
                    "startOffset": 19874
                },
                "b0040": {
                    "endOffset": 19879,
                    "startOffset": 19874
                }
            },
            "secId": "s0005",
            "sentence": "However, 2 vaccines against serogroup B have been approved for use in several countries [6\u20138].",
            "startOffset": 19786,
            "title": "Introduction"
        },
        {
            "endOffset": 19168,
            "parents": [],
            "secId": "s0005",
            "sentence": "Neisseria meningitidis is one of the leading causes of meningitis and sepsis worldwide.",
            "startOffset": 19081,
            "title": "Introduction"
        },
        {
            "endOffset": 21436,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 21435,
                    "startOffset": 21428
                },
                "b0080": {
                    "endOffset": 21435,
                    "startOffset": 21428
                }
            },
            "secId": "s0005",
            "sentence": "Due to the low incidence of IMD, vaccine efficacy studies cannot be carried out and the introduction of meningococcal vaccines into national vaccination programs is needed to assess vaccine effectiveness against serogroup B. To date, the only effectiveness data are available from the United Kingdom, where at 10 months after the start of the program, 4CMenB demonstrated an overall field effectiveness against IMD of 83% after the second dose in infants [15,16].",
            "startOffset": 20973,
            "title": "Introduction"
        },
        {
            "endOffset": 30100,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 30099,
                    "startOffset": 30095
                }
            },
            "secId": "s0035",
            "sentence": "Participants with positive enc-hSBA results (SBA at 1:4 dilution) were considered protected against the corresponding serogroup B meningococcal strains [14].",
            "startOffset": 29943,
            "title": "Serological assays"
        },
        {
            "endOffset": 23655,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase IIb, controlled, observer-blind study conducted between May 2014 and June 2015 in 8 centers in the US.",
            "startOffset": 23536,
            "title": "Study design and participants"
        },
        {
            "endOffset": 44811,
            "parents": [],
            "secId": "s0100",
            "sentence": "GlaxoSmithKline Biologicals SA took responsibility for all costs associated with the development and publishing of the present manuscript.",
            "startOffset": 44673,
            "title": "Funding"
        },
        {
            "endOffset": 27448,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The immunogenicity of 2 and 3 doses of MenABCWY against 4 reference strains specific to serogroup B vaccine antigens and against 4 strains specific to each meningococcal serogroups A, C, W and Y, and safety and reactogenicity were also assessed.",
            "startOffset": 27203,
            "title": "Study objectives"
        },
        {
            "endOffset": 28507,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 28404,
                    "startOffset": 28400
                },
                "b0120": {
                    "endOffset": 28506,
                    "startOffset": 28502
                }
            },
            "secId": "s0030",
            "sentence": "In total, 442 serogroup B strains [23] were obtained from a systematically collected CDC repository of US IMD strains from 2000 to 2008 [24].",
            "startOffset": 28366,
            "title": "110 strain panel"
        },
        {
            "endOffset": 27747,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 27746,
                    "startOffset": 27742
                }
            },
            "secId": "s0025",
            "sentence": "The composition of MenACWY-CRM (Menveo, GSK) was previously described [22].",
            "startOffset": 27672,
            "title": "Vaccines"
        },
        {
            "endOffset": 28884,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The method used for strain qualification for the evaluation of the BoC provided by MenABCWY is presented in Text S3 and the qualified strains that appeared representative of the 442 strain-panel in Table S1.",
            "startOffset": 28677,
            "title": "110 strain panel"
        },
        {
            "endOffset": 22593,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 22592,
                    "startOffset": 22588
                }
            },
            "secId": "s0005",
            "sentence": "An alternative approach is the use of an hSBA using the endogenous complement present in serum samples (enc-hSBA), instead of exogenous complement from seronegative donors (hSBA) [14].",
            "startOffset": 22409,
            "title": "Introduction"
        },
        {
            "endOffset": 41916,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 41915,
                    "startOffset": 41908
                },
                "b0155": {
                    "endOffset": 41915,
                    "startOffset": 41908
                },
                "b0160": {
                    "endOffset": 41915,
                    "startOffset": 41908
                }
            },
            "secId": "s0085",
            "sentence": "Future research may include an assessment of the latest strains isolated by the CDC, so that the BoC provided by MenABCWY can be estimated for newly emerged serogroup B strains, including those identified in recent university outbreaks [30\u201332].",
            "startOffset": 41672,
            "title": "Discussion"
        },
        {
            "endOffset": 29815,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 29814,
                    "startOffset": 29810
                }
            },
            "secId": "s0035",
            "sentence": "Participants with positive enc-hSBA results (SBA at 1:4 dilution) were considered protected against the corresponding serogroup B meningococcal strains [14].",
            "startOffset": 29658,
            "title": "Serological assays"
        },
        {
            "endOffset": 41508,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 41507,
                    "startOffset": 41500
                },
                "b0135": {
                    "endOffset": 41507,
                    "startOffset": 41500
                }
            },
            "secId": "s0085",
            "sentence": "However, the systemic AEs were reported with lower rates in our study compared with previous trials [26,27].",
            "startOffset": 41400,
            "title": "Discussion"
        },
        {
            "endOffset": 32107,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Medically-attended AEs and serious AEs were recorded throughout the study.",
            "startOffset": 32033,
            "title": "Safety"
        },
        {
            "endOffset": 25010,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Eligible participants in the parent study were healthy adolescents aged 10\u201318 years; participants who had received the vaccines according to protocol and completed the study were eligible for the extension.",
            "startOffset": 24804,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37562,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Across all 4 strains specific for 4CMenB components, the percentage of participants with enc-hSBA titers \u22651:4 and HT-hSBA titers \u22651:5, and hSBA geometric mean titers (GMTs) were higher in the MenABCWY than in the Control group at each timepoint post-vaccination (Tables S4, S5).",
            "startOffset": 37284,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33510,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Strain-specific BoC was defined as [1 \u2212 (percentage of samples without enc-hSBA activity in the MenABCWY group/percentage of samples without enc-hSBA activity in the Control group)] \u00d7 100.",
            "startOffset": 33322,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 33940,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Assuming each participant was tested for \u223c33 strains, 3960 measures would be available in each group.",
            "startOffset": 33839,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35984,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Fig. 4 represents strain-specific BoCs provided by the MenABCWY vaccine.",
            "startOffset": 35912,
            "title": "Strain-specific breadth of coverage"
        },
        {
            "endOffset": 39699,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 39698,
                    "startOffset": 39694
                }
            },
            "secId": "s0085",
            "sentence": "As expected, our results suggest that a certain level of natural immunity against serogroup B-caused disease can be acquired by adolescence [29].",
            "startOffset": 39554,
            "title": "Discussion"
        },
        {
            "endOffset": 32762,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Strain-specific BoC was defined as [1 \u2212 (percentage of samples without enc-hSBA activity in the MenABCWY group/percentage of samples without enc-hSBA activity in the Control group)] \u00d7 100.",
            "startOffset": 32574,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28075,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 28074,
                    "startOffset": 28070
                }
            },
            "secId": "s0025",
            "sentence": "The composition of MenACWY-CRM (Menveo, GSK) was previously described [22].",
            "startOffset": 28000,
            "title": "Vaccines"
        },
        {
            "endOffset": 44672,
            "parents": [],
            "secId": "s0100",
            "sentence": "This study was funded by Novartis Vaccines and Diagnostics Inc., now part of the GSK group of companies.",
            "startOffset": 44568,
            "title": "Funding"
        },
        {
            "endOffset": 42101,
            "parents": [],
            "secId": "s0085",
            "sentence": "Additional strain panels will have to be assessed for other countries which could potentially benefit from MenABCWY vaccination, although this exercise may prove technically difficult.",
            "startOffset": 41917,
            "title": "Discussion"
        },
        {
            "endOffset": 41260,
            "parents": [],
            "secId": "s0085",
            "sentence": "In our study, injection site pain was reported by 62\u201382% of adolescents across all MenABCWY doses, compared with 36% after administration of the single MenACWY-CRM dose in the Control group.",
            "startOffset": 41070,
            "title": "Discussion"
        },
        {
            "endOffset": 31251,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 30957,
                    "startOffset": 30953
                }
            },
            "secId": "s0035",
            "sentence": "The high throughput hSBA (HT-hSBA) [25] using human plasma as the source of exogenous complement (plasmapheresis was performed using citrate as the anticoagulant and heparin was included in the buffer of the HT-hSBA) was used to measure antibodies against test strains specific for serogroup B vaccine components and ACWY serogroups.",
            "startOffset": 30918,
            "title": "Serological assays"
        },
        {
            "endOffset": 39147,
            "parents": [],
            "secId": "s0085",
            "sentence": "The overall BoC of the MenABCWY vaccine was estimated at 67% at 1 month after the administration of 2 doses and 71% at 1 month after administration of a third dose in adolescents, when compared with a single dose of MenACWY-CRM.",
            "startOffset": 38919,
            "title": "Discussion"
        },
        {
            "endOffset": 36297,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "For the majority of tested serogroup B strains, comparable strain-specific BoCs were observed at 1 month after 2 and 3 doses and at 4 months after 2 and 3 doses, respectively (e. g., 59.1% and 65.5%, and 38.2% and 46.4% had a strain-specific BoC >60% at study months 3 and 7 and 6 and 10, respectively; Table S3).",
            "startOffset": 35984,
            "title": "Strain-specific breadth of coverage"
        },
        {
            "endOffset": 35552,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Overall, in both groups, for the same percentage of strains killed, the percentage of participants with positive enc-hSBA results was similar 1 month post-vaccinations (Fig. 3B and D) and 4 month post-vaccinations (Fig. 3C and E), respectively.",
            "startOffset": 35308,
            "title": "Participants\u2019 distribution by percentages of strains killed"
        },
        {
            "endOffset": 31587,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 31417,
                    "startOffset": 31410
                },
                "b0135": {
                    "endOffset": 31417,
                    "startOffset": 31410
                },
                "b0140": {
                    "endOffset": 31417,
                    "startOffset": 31410
                }
            },
            "secId": "s0035",
            "sentence": "Dilution thresholds of 1:4 and 1:8 were previously used in MenABCWY clinical trials as cut-off values against serogroup B strains and against serogroups ACWY [26\u201328], respectively, and were also employed in the current study, pending the final assay validation and the determination of validation-derived lower limit of quantification.",
            "startOffset": 31252,
            "title": "Serological assays"
        },
        {
            "endOffset": 23153,
            "parents": [],
            "secId": "s0005",
            "sentence": "This will contribute to the evaluation of the vaccine\u2019s ability to potentially protect against these strains in real-world-settings, in an approximation of the vaccine\u2019s effectiveness (Fig. 1).",
            "startOffset": 22960,
            "title": "Introduction"
        },
        {
            "endOffset": 27671,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The investigational vaccine MenABCWY was prepared aseptically just prior to administration by reconstituting the lyophilized MenACWY component with a liquid suspension containing serogroup B components (Text S2).",
            "startOffset": 27459,
            "title": "Vaccines"
        },
        {
            "endOffset": 22181,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 21998,
                    "startOffset": 21991
                },
                "b0100": {
                    "endOffset": 21998,
                    "startOffset": 21991
                },
                "b0105": {
                    "endOffset": 21998,
                    "startOffset": 21991
                }
            },
            "secId": "s0005",
            "sentence": "However, the presence and expression of vaccine antigens can vary greatly among circulating strains [19\u201321] and ideally, a large panel of strains should be assessed with hSBA to evaluate vaccine coverage, rather than relying on immunogenicity using antigen-specific laboratory test strains.",
            "startOffset": 21891,
            "title": "Introduction"
        },
        {
            "endOffset": 44257,
            "parents": [],
            "secId": "s0090",
            "sentence": "The BoC provided by 2 doses of the MenABCWY vaccine against a randomly selected panel of 110 endemic US N. meningitidis serogroup B invasive disease strains when compared with a single dose of the MenACWY-CRM vaccine was similar to that of 3 doses (67% and 71%, respectively).",
            "startOffset": 43981,
            "title": "Conclusions"
        },
        {
            "endOffset": 32573,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The overall BoC was defined as (1 \u2212 relative risk) \u00d7 100, where the relative risk was calculated as the average (across the 110 strains in the panel) of the ratio between the percentages of samples without SBA at 1:4 dilution in the MenABCWY group and the percentages of samples without SBA at 1:4 dilution in the Control group, using a generalized linear model with treatment group and strain as independent variables, and adjusted by centre.",
            "startOffset": 32130,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29657,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The enc-hSBA assay used to evaluate the BoC provided by MenABCWY against serogroup B strains is presented in detail in Text S4.",
            "startOffset": 29530,
            "title": "Serological assays"
        },
        {
            "endOffset": 38158,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Unsolicited AEs and medically attended AEs were reported by similar percentages of participants in the 2 groups.",
            "startOffset": 38046,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 42890,
            "parents": [],
            "secId": "s0085",
            "sentence": "Of note, our analysis of the BoC provided by MenABCWY in the tested strain panel used as control MenACWY-CRM (the current standard-of-care), but not 4CMenB.",
            "startOffset": 42734,
            "title": "Discussion"
        },
        {
            "endOffset": 32032,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The investigators determined the severity of solicited AEs and assessed the relationship between all AEs and vaccination.",
            "startOffset": 31911,
            "title": "Safety"
        },
        {
            "endOffset": 23496,
            "parents": [],
            "secId": "s0005",
            "sentence": "Immunogenicity against antigen-specific test strains by traditional hSBA and safety of MenABCWY were also evaluated.",
            "startOffset": 23380,
            "title": "Introduction"
        },
        {
            "endOffset": 30769,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 30599,
                    "startOffset": 30592
                },
                "b0135": {
                    "endOffset": 30599,
                    "startOffset": 30592
                },
                "b0140": {
                    "endOffset": 30599,
                    "startOffset": 30592
                }
            },
            "secId": "s0035",
            "sentence": "Dilution thresholds of 1:4 and 1:8 were previously used in MenABCWY clinical trials as cut-off values against serogroup B strains and against serogroups ACWY [26\u201328], respectively, and were also employed in the current study, pending the final assay validation and the determination of validation-derived lower limit of quantification.",
            "startOffset": 30434,
            "title": "Serological assays"
        },
        {
            "endOffset": 28115,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The placebo was a 0.9% saline solution.",
            "startOffset": 28076,
            "title": "Vaccines"
        },
        {
            "endOffset": 31795,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Adverse events (AEs) were recorded on diary cards.",
            "startOffset": 31745,
            "title": "Safety"
        },
        {
            "endOffset": 33723,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "A sample size of 150 participants per study group was planned for enrollment in the parent study.",
            "startOffset": 33626,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29530,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Approximately 20 mL of blood were collected from all participants at each pre-specified timepoint (Fig. 2).",
            "startOffset": 29423,
            "title": "Serological assays"
        },
        {
            "endOffset": 44354,
            "parents": [],
            "secId": "s0090",
            "sentence": "The MenABCWY vaccine was immunogenic with a clinically acceptable safety profile in adolescents.",
            "startOffset": 44258,
            "title": "Conclusions"
        },
        {
            "endOffset": 24165,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Adolescents who completed the parent study were invited to participate in an extension study, in which participants from the MenABCWY group received a third dose of MenABCWY and participants from the Control group received a second placebo dose at 6 months after the first vaccination (Fig. 2).",
            "startOffset": 23871,
            "title": "Study design and participants"
        },
        {
            "endOffset": 25208,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from participants aged \u226518 years or parents/legal guardians of 10\u201317-year-olds prior to enrollment, and assent was obtained from participants \u226418 years of age.",
            "startOffset": 25011,
            "title": "Study design and participants"
        },
        {
            "endOffset": 28676,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Overall, 140 strains were randomly selected from the repository, of which 139 were shipped to the GSK Clinical Science Laboratory in Marburg, Germany for qualification.",
            "startOffset": 28508,
            "title": "110 strain panel"
        },
        {
            "endOffset": 39337,
            "parents": [],
            "secId": "s0085",
            "sentence": "Compared with a 2-dose schedule, the administration of a third MenABCWY dose had a limited impact on the BoC estimated across the 110 endemic US N. meningitidis serogroup B invasive strains.",
            "startOffset": 39147,
            "title": "Discussion"
        },
        {
            "endOffset": 19532,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 19531,
                    "startOffset": 19528
                }
            },
            "secId": "s0005",
            "sentence": "Predominant disease-causing serogroups vary geographically, but 5 of them (A, B, C, W, Y) are responsible for the majority of meningococcal disease cases worldwide, with serogroup X also emerging recently as an important cause of IMD [3].",
            "startOffset": 19294,
            "title": "Introduction"
        },
        {
            "endOffset": 26885,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Secondary objectives included evaluating the overall BoC provided by MenABCWY vaccination at 4 months after 2 and 3 vaccine doses.",
            "startOffset": 26755,
            "title": "Study objectives"
        },
        {
            "endOffset": 38045,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The most frequent local and general AEs were pain and headache and fatigue.",
            "startOffset": 37970,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 21890,
            "parents": [],
            "secId": "s0005",
            "sentence": "For serogroup B, immunogenicity is measured by hSBA against test strains specific for each vaccine antigen.",
            "startOffset": 21783,
            "title": "Introduction"
        },
        {
            "endOffset": 35246,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Five out of the 110 strains were consistently SBA-killing positive (for all samples in both treatment groups) and were excluded from evaluation of the BoC at each timepoint.",
            "startOffset": 35073,
            "title": "Overall breadth of coverage against serogroup B strains panel"
        },
        {
            "endOffset": 33626,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "A detailed description of the method used to calculate the overall and strain-specific BoCs is provided in Text S5.",
            "startOffset": 33511,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 40394,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 40346,
                    "startOffset": 40342
                },
                "b0135": {
                    "endOffset": 40393,
                    "startOffset": 40389
                }
            },
            "secId": "s0085",
            "sentence": "Our results were similar to those observed in previous studies with 2 doses of the MenABCWY vaccine administered 2 months apart in healthy adolescents aged 10\u201318 years from the US and Poland [26] and in 11\u201318-year-olds from Latin America [27].",
            "startOffset": 40151,
            "title": "Discussion"
        },
        {
            "endOffset": 40150,
            "parents": [],
            "secId": "s0085",
            "sentence": "In this study, 2 and 3 MenABCWY doses induced a robust immune response against serogroup B and ACWY test strains, in terms of percentages of participants with HT-hSBA titers above pre-specified thresholds.",
            "startOffset": 39945,
            "title": "Discussion"
        },
        {
            "endOffset": 24670,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A complete list of inclusion/exclusion criteria is presented in the Supplementary Material, Text S1.",
            "startOffset": 24570,
            "title": "Study design and participants"
        },
        {
            "endOffset": 43235,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 43234,
                    "startOffset": 43230
                }
            },
            "secId": "s0085",
            "sentence": "A previous study showed that 2 doses of 4CMenB induced higher antibody responses against serogroup B antigen-specific test strains compared to 2 doses of MenABCWY, both in terms of GMT fold-increases from pre-vaccination levels and the percentage of participants with hSBA titer \u22655 against each of the 4 serogroup B indicator strains used [26].",
            "startOffset": 42891,
            "title": "Discussion"
        },
        {
            "endOffset": 26755,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary objective was to assess the overall BoC provided by MenABCWY vaccination against a panel of 110 endemic US strains, randomly selected from the Centers for Disease Control and Prevention (CDC) repository of 442 N. meningitidis serogroup B invasive disease strains, as measured by bactericidal activity at 1:4 dilution using enc-hSBA, at 1 month after 2 and 3 vaccine doses, when compared to a single dose of MenACWY-CRM.",
            "startOffset": 26324,
            "title": "Study objectives"
        },
        {
            "endOffset": 28347,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Vaccines were prepared as 0.5 mL doses, and then administered intramuscularly, preferably into the deltoid region of the non-dominant arm, by designated un-blinded staff who did not participate in any evaluation of the participants.",
            "startOffset": 28115,
            "title": "Vaccines"
        },
        {
            "endOffset": 38918,
            "parents": [],
            "secId": "s0085",
            "sentence": "This is the first study using a direct serological assessment to evaluate the BoC provided by the investigational MenABCWY vaccine against a broad panel of US invasive serogroup B isolates.",
            "startOffset": 38729,
            "title": "Discussion"
        },
        {
            "endOffset": 38532,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Unsolicited AEs and medically attended AEs were reported by similar percentages of participants in the 2 groups.",
            "startOffset": 38420,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 39553,
            "parents": [],
            "secId": "s0085",
            "sentence": "Prior to vaccination, all participants in both groups had bactericidal activity against only 5 out of the 110 invasive strains selected from the CDC repository, which contains strains collected between 2000 and 2008.",
            "startOffset": 39337,
            "title": "Discussion"
        },
        {
            "endOffset": 37201,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Across all post-vaccination timepoints, 89\u2013100% of participants in the MenABCWY group had HT-hSBA titers \u22651:8 against ACWY serogroups, except for serogroup A at 4 months post-second (69%) and third dose (86%); GMTs were higher in the MenABCWY group compared to the control group (Tables S6, S7).",
            "startOffset": 36906,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 29402,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The method used for strain qualification for the evaluation of the BoC provided by MenABCWY is presented in Text S3 and the qualified strains that appeared representative of the 442 strain-panel in Table S1.",
            "startOffset": 29195,
            "title": "110 strain panel"
        },
        {
            "endOffset": 29194,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Overall, 140 strains were randomly selected from the repository, of which 139 were shipped to the GSK Clinical Science Laboratory in Marburg, Germany for qualification.",
            "startOffset": 29026,
            "title": "110 strain panel"
        },
        {
            "endOffset": 29942,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The enc-hSBA assay used to evaluate the BoC provided by MenABCWY against serogroup B strains is presented in detail in Text S4.",
            "startOffset": 29815,
            "title": "Serological assays"
        },
        {
            "endOffset": 36905,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Across all 4 strains specific for 4CMenB components, the percentage of participants with enc-hSBA titers \u22651:4 and HT-hSBA titers \u22651:5, and hSBA geometric mean titers (GMTs) were higher in the MenABCWY than in the Control group at each timepoint post-vaccination (Tables S4, S5).",
            "startOffset": 36627,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 38718,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "One serious AE (mild pharyngitis, occurring 24 days after the MenACWY-CRM dose and resolved after 16 days from onset) was reported and assessed as non-related to vaccination (Table S9).",
            "startOffset": 38533,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 40860,
            "parents": [],
            "secId": "s0085",
            "sentence": "However, in our study antibody HT-hSBA GMTs were higher at 4 months after the third MenABCWY dose than after the second one for all 4 serogroup B vaccine components except factor H binding protein.",
            "startOffset": 40663,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X18309460",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "jwelsch@path.org",
                "first": "Jo Anne",
                "initial": "J.A.",
                "last": "Welsch"
            },
            {
                "email": "ssenders@senderspediatrics.com",
                "first": "Shelly",
                "initial": "S.",
                "last": "Senders"
            },
            {
                "email": "bessink@mcrmed.com",
                "first": "Brandon",
                "initial": "B.",
                "last": "Essink"
            },
            {
                "email": "tck@heartlandresearch.com",
                "first": "Thomas",
                "initial": "T.",
                "last": "Klein"
            },
            {
                "email": "smolenov@gmail.com",
                "first": "Igor",
                "initial": "I.",
                "last": "Smolenov"
            },
            {
                "email": "paola.x.pedotti@gsk.com",
                "first": "Paola",
                "initial": "P.",
                "last": "Pedotti"
            },
            {
                "email": "silvia.x.barbi@gsk.com",
                "first": "Silvia",
                "initial": "S.",
                "last": "Barbi"
            },
            {
                "email": "bikashverma@usa.com",
                "first": "Bikash",
                "initial": "B.",
                "last": "Verma"
            },
            {
                "email": "daniela.x.toneatto@gsk.com",
                "first": "Daniela",
                "initial": "D.",
                "last": "Toneatto"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.07.016",
        "firstpage": "5309",
        "issn": "0264410X",
        "keywords": [
            "Adolescents",
            "Breadth of coverage",
            "Endogenous complement human bactericidal assay",
            "MenABCWY",
            "Meningococcal vaccine",
            "Neisseria meningitidis"
        ],
        "lastpage": "5317",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents \u2013 Results from a randomized, controlled, observer-blind phase II study"
    }
}